UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.)*

Nurix Therapeutics Inc.
(Name of Issuer)
Common Stock, par value \$0.001 per share
(Title of Class of Securities)
67080M103
(CUSIP Number)
December 31, 2023
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Ac of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
inotes).

			·				
	NAMES OF REPORTING PERSONS						
1.	ARK Investment Management LLC						
2	CHECK TH	IE APPRO	OPRIATE BOX IF A MEMBER OF A GROUP				
2.				(a) □ (b) □			
	SEC USE O	NLV		(0) 🗆			
3.	SEC USE ONLI						
	CITIZENSHIP OR PLACE OF ORGANIZATION						
4.	Delaware, United States						
	2014//1410,0	1	_				
		_	SOLE VOTING POWER				
		5.	3,194,999				
NUM	IBER OF		SHARED VOTING POWER				
	IARES FICIALLY	LLY	0				
	NED BY						
EACH		_	SOLE DISPOSITIVE POWER				
	ORTING ON WITH		3,194,999				
			SHARED DISPOSITIVE POWER				
		8.	0				
9.	AGGREGA	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON					
9.	3,194,999	3,194,999					
	CHECK IF	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES					
10.							
11.	PERCENT	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)					
11.	6.59%						
	TYPE OF R	REPORTI	NG PERSON				
12.	IA	IA					
	173						

13G

Page 2 of 5 Pages

CUSIP No. 67080M103

CUSIP No. 67080M103	13G	Page 3 of 5 Pages
Item 1(a) Name of issuer:		
Nurix Therapeutics Inc.		
Item 1(b) Address of issuer's principal exec	cutive offices:	
1700 Owens Street, Suite 205 San Francisco, CA 94158		
Item 2(a) Name of person filing:		
ARK Investment Management LLC		
Item 2(b) Address or principal business off	ice or, if none, residence:	
ARK Investment Management LLC 200 Central Avenue St. Petersburg, FL 33701		
Item 2(c) Citizenship:		
Delaware, United States		
Item 2(d) Title of class of securities:		
Common Shares, par value \$0.001 per share		
Item 2(e) CUSIP No.:		
67080M103		
Item 3. If this statement is filed pursuant to	o §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the pers	son filing is a:
(a) \square Broker or dealer registered under section	on 15 of the Act (15 U.S.C. 780);	
(b) ☐ Bank as defined in section 3(a)(6) of the	e Act (15 U.S.C. 78c);	
(c) ☐ Insurance company as defined in section	on 3(a)(19) of the Act (15 U.S.C. 78c);	
(d) \square Investment company registered under s	section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8));
(e) ⊠ An investment adviser in accordance w	rith § 240.13d-1(b)(1)(ii)(E);	
(f) \square An employee benefit plan or endowment	nt fund in accordance with § 240.13d-1(b)(1)(ii)(F);	
(g) \square A parent holding company or control p	erson in accordance with § 240.13d-1(b)(1)(ii)(G);	
(h) \square A savings associations as defined in Se	ection 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);	
(i) ☐ A church plan that is excluded from the U.S.C. 80a-3);	he definition of an investment company under section 3(c)(14) of	f the Investment Company Act of 1940 (15
(j) □ A non-U.S. institution in accordance wi	ith § 240.13d-1(b)(1)(ii)(J);	
(k) \square Group, in accordance with § 240.13d-type of institution:	(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with	§ 240.13d-1(b)(1)(ii)(J), please specify the

CUSIP No. 67080M103		13G	Page 4 of 5 Pages			
Item 4	4. Ownership	•				
(a)	Amount beneficially owned:					
	3,194,999					
(b)	Percent of class:					
	6.59%					
(c)	Number of shares as to which such person has:					
	(i) Sole power to vote or to direct the vote: 3,194,999					
	(ii) Shared power to vote or to direct the vote: 0					
	(iii) Sole power to dispose or to direct the disposition of: 3,194,999					
	(iv) Shared power to dispose or to direct the disposition of: 0					
Item :	5. Ownership of 5 Percent or Less of a Cla	ss.				
Not ap	oplicable.					
Item (6. Ownership of More than 5 Percent on E	Schalf of Another Person.				
		her person has the right to receive or the power to di resents more than five percent of the number of outsta				
	7. Identification and Classification of the col Person.	Subsidiary Which Acquired the Security Being R	deported on by the Parent Holding Company of			
Not ap	oplicable.					
Item 8	8. Identification and Classification of Men	nbers of the Group.				
Not ap	oplicable.					
Item 9	O. Notice of Dissolution of Group.					
Not ap	oplicable.					

CUSIP No. 67080M103	13G	Page 5 of 5 Pages
---------------------	-----	-------------------

Item 10. Certifications.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

The reporting persons agree that this statement is filed on behalf of each of them.

Dated: January 29, 2024

ARK Investment Management LLC

By: /s/ Kellen Carter

Name: Kellen Carter

Title: Chief Compliance Officer